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ABSTRACT 
The development of effective vaccines against HIV-1 infection constitutes one of the 
major challenges in viral immunology. One of the protein candidates in vaccination 
against this virus is p24, since it is a conserved HIV antigen that has cytotoxic and 
helper T cell epitopes as well as B cell epitopes that may jointly confer enhanced 
protection against infection when used in immunization-challenge approaches. In this 
context, the adjuvant effect of EDA (used as EDAp24 fusion protein) and poly(I:C), as 
agonists of TLR4 and TLR3, respectively, was assessed in p24 immunizations using a 
recombinant Listeria monocytogenes HIV-1 Gag proteins (Lm-Gag, where p24 is the 
major antigen) for challenge in mice. Immunization with EDAp24 fusion protein together 
with poly(I:C) adjuvant induced a specific p24 IFN- production (Th1 profile) as well as 
protection against a Lm-Gag challenge, suggesting an additive or synergistic effect 
between both adjuvants. The combination of EDA (as a fusion protein with the antigen, 
which may favor antigen targeting to dendritic cells through TLR4) and poly(I:C) could 
thus be a good adjuvant candidate to enhance the immune response against HIV-1 
proteins and its use may open new ways in vaccine investigations on this virus. 
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1. INTRODUCTION 
The worldwide distribution of human immunodeficiency virus type 1 (HIV-1) infection 
and associated functional impairment and mortality point out the urgent need for an 
effective vaccine, which should induce both neutralizing antibodies and a potent cell 
mediated immunity. This would allow both the neutralization of free virus and the 
elimination of infected cells [1, 2]. In HIV-1, p24 is the major structural capsid protein 
encoded by the gag gene, which forms the virus core by homodimerization. HIV p24 
protein has a variety of CTL/CD8 epitopes 
(www.hiv.lanl.gov/content/immunology/maps/ctl/p24.html), triggering cytotoxic T-cell 
immune responses and constituting an important target for cell mediated immunity 
(CMI) against the virus. It has also highly conserved T helper cell epitopes useful for 
priming a broadly reactive immune response to HIV-1 [3]. T helper function may 
enhance the production of neutralizing antibodies directed to envelope proteins [4]. 
Therefore, the p24 antigen is an attractive candidate for the development of an 
effective anti-HIV-1 vaccine or therapeutical drug. The p24 protein has also B cell 
epitopes, leading to the production of antibodies to this protein that are frequently used 
in lentiviral diagnosis and as markers of disease progression, since asymptomatic 
seropositive individuals display high p24-specific antibody titers, whereas acute HIV-1 
infection and progression is associated with the reduction or absence of p24 specific 
antibodies [5].  
Aluminum salts (Alum) have been approved as the only adjuvant of human application 
for many decades since the experiments by Glenny and collaborators [6]. However, 
this adjuvant does not enhance CTL responses [7] and may induce undesirable side-
effects. Thus, the development of new adjuvants to enhance cell and antibody 
mediated immunity when administered with recombinant proteins is crucial to obtain 
effective vaccines. In this context, pathogen-associated molecular patterns (PAMP) 
have been confirmed as potent immunomodulators due to their interaction with 
dendritic cells. Their signaling pathways starts in pattern recognition receptors (PPRs) 
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such as the Toll-like receptors (TLR) specific for each PAMP and ends triggering both, 
innate and adaptive immune responses [8].  
The cellular glycoprotein fibronectin (FN) has multiple isoforms generated from a single 
gene by alternative splicing of three exons. One of these isoforms is the extra domain 
A (EDA) presented during embryonic development and produced in response to tissue 
injury. EDA-containing fibronectin fragments or specific domains of fibronectin are also 
believed to play important roles in physiological and pathological processes such as 
wound healing in adults and rheumatoid arthritis [9, 10]. Although information on the 
biological properties of EDA is limited, it is known that EDA induces NF-κ factor 
activation, which is involved in connective tissue destruction, tissue remodeling in 
response to chronic inflammatory lesion development, and in monocyte and dendritic 
cell migration throughout their basal membrane. These EDA associated effects are 
triggered in response to the interaction between EDA and its specific TLR-4, a receptor 
that also interacts with LPS of Gram negative bacteria [11, 12]. Altogether, these 
observations suggest that the expression of EDA in response to tissue injury, or other 
cellular warning signals, might induce recruitment of dendritic cells to the site of injury 
and trigger their subsequent maturation. Indeed, previous work demonstrates that 
EDA, as fusion protein, may constitute a strategy to target viral or tumoral antigens to 
dendritic cells in vivo [11, 13, 14]. Therefore, the capacity of EDA to induce dendritic 
cell maturation through TLR4 activation may also favor antigen uptake, expression of 
co-stimulatory signals, antigen presentation and the induction of anti-viral or anti-
tumoral T cell responses [11, 13].  
Double stranded RNA is regarded as a PAMP and may be found in some RNA viruses 
and also in dsRNA intermediates often produced during viral replication, activating the 
immune system. Poly(I:C), a synthetic dsRNA that mimics the effects of naturally 
occurring dsRNA, is thus frequently used as an adjuvant in both, antitumor treatment 
and vaccine development, mainly because of its effects activating CD8 T cells and NK 
cells. Poly(I:C) binds TLR3 and this interaction is thought to be crucial for driving cell-
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mediated immune responses. A synergistic activity between different TLR agonists 
may trigger more vigorous T cell responses [15, 16]. 
On the basis of the characteristics and immunogenic properties of HIV-1 p24 and 
adjuvant characteristics of EDA and poly(I:C), this work aims to determine whether 
EDA and poly(I:C) could be used as HIV p24 immunopotentiators.  
 
2. MATERIALS AND METHODS 
2.1. Production and purification of EDAp24 and p24 recombinant proteins 
Plasmid pET20b-EDA [11] was used for the construction pET20b-EDAp24, which 
expressed a fusion protein containing HIV-1 p24 linked to the carboxy-terminus of EDA 
and carrying six histidines at the carboxy-terminus. Plasmid pET20b-p24 expressing 
p24 alone and linked to a six-histidine tag at the carboxy-terminus was constructed 
using conventional cloning techniques and a plasmid (kindly provided by Prof. I. Jones, 
University of Reading, UK) containing HIV-1 p24 gene as template. The resulting PCR 
product was subcloned in pET20b commercial plasmid (Novagen). Plasmids pET20-
EDAp24 and pET20b-p24 were sequenced and then transfected into BL21(DE3) cells 
(Amershan Pharmacia Biosciences) for the expression of the corresponding 
recombinant proteins.  
EDAp24 was expressed using an auto-inducible medium, as previously described [17] 
except for the bacteria disruption by sonication and incubation with lysozyme, anti-
metalloproteases, Triton, DNAse and RNAse solution. The p24 single recombinant 
protein was expressed as previously described [18] except for a 6M guanidine 
hydrochloride treatment to unfold p24 from bacterial inclusion bodies, followed by a 
refolding by a guanidine hydrochloride decreasing gradient (6-0M) in PBS. Both protein 
solutions were stored at 4ºC until protein purification in a pre-charged nickel-sepharose 
column (HisTrap HP, GE Healthcare). His-tagged recombinant proteins were 
recovered by a binding buffer with an increasing gradient of imidazole (0-500 mM) and 
dialyzed for 2 days at 4ºC. Additionally, to avoid the presence of eventual bacterial 
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contaminants, the protein preparations were filtered through a 0.2 μm membrane 
(Millipore®). Residual endotoxins were removed using Profos EndoTrap® columns 
(Hyglos Gmbh), as previously described [11, 12]. The resulting proteins were stored at 
-80ºC in PBS until use. 
2.2. Characterization of protein preparations 
After confirming the absence of bacterial contaminants (by plating in agar and 
incubation of plates at 37ºC for 5 days) and endotoxins (by Quantitative Chromogenic 
Limulus Amebocyte Lysate assay; Cambrex), the protein concentration was 
determined by the standard Bradford method (Bio-Rad Laboratories Inc.). Purity and 
size of recombinant proteins were assessed by SDS-PAGE [19] followed by Coomasie 
Brilliant Blue R-250 staining [20]. Since both proteins carried histidine groups, their 
electrophoretic profiles were assessed by Western-Blot (WB) with an anti-polyhistidine 
serum-peroxidase conjugate (1:2,500; Sigma). For individual detection of EDAp24 and 
p24, WB was performed with a mouse monoclonal antibody anti-p24 (1:250) as primary 
antibody (NIBSC, WHO-UNAIDS HIV Vaccine Initiative-Health Protection Agency) and 
an anti-IgG horseradish peroxidase conjugate (1:2,500) as secondary antibody (Nordic 
Immunological Laboratories). Reactions were developed with diaminobenzidine and 
hydrogen peroxide. A recombinant EDA protein and a rabbit anti-EDA antibody, used 
as control in this and subsequent assays, were obtained as previously described [11, 
13]. 
2.3. Evaluation of in vitro biological activity of EDAp24 and p24 proteins  
The epitopic conformation of both EDAp24 and p24 was determined by a sandwich 
ELISA in 96-well microtiter plates (Thermo Scientific Nunc®) coated overnight at 4ºC 
with 1 µg/well of a sheep affinity purified anti-HIV-1 p24 antibody (NIBSC, WHO-
UNAIDS HIV Vaccine Initiative-Health Protection Agency) in carbonate-bicarbonate 
buffer (pH 8.6). Then, the recombinant protein (100 L/well) and the mouse anti-p24 
biotinylated antibody (NIBSC, WHO-UNAIDS HIV Vaccine Initiative-Health Protection 
Agency) diluted 1:100 were added to plates and plates were incubated (overnight at RT 
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for the protein, and 2 h at RT for the antibody). Finally, the reaction was developed by 
adding streptavidine-peroxidase conjugate (1:500) and incubating (2 h at 37ºC) with 
3,3’,5,5’-Tetramethylbenzidine substrate solution. Peroxidase activity was stopped with 
2M H2SO4 and absorbance measured at 450 nm in a MultiSkan EX apparatus 
(Labsystem).  
2.4. Immunological studies in mice 
Mice from Charles River International (France) were accommodated in the animal 
facilities of the Universidad Pública de Navarra (UPNA; registration code ES/31-2016-
000002-CR-SU-US). Mice experiments were performed in compliance with the current 
European and national regulations, and with the approval of the Comité de Ética, 
Experimentación Animal y Bioseguridad (CEEAB) of UPNA and Navarra Government.  
Groups of 8-10 week-old female BALB/c mice (n=8) were intraperitoneally (IP) 
inoculated with 0.1 mL of the following suspensions prepared in PBS: i) 30 µg of p24; ii) 
50 µg of EDAp24 (corresponding to 30 µg p24 and 20 µg EDA); iii) 30 µg of p24 mixed 
with 50 µg poly (I:C) (Amersham Pharmacia Biosciences); iv) 50 µg of EDAp24 mixed 
with 50 µg poly (I:C); v) 20 µg EDA mixed with 50 µg poly (I:C); or vi) PBS.  
2.4.1. Cellular immune response of interferon gamma  
Seven days after immunization, 3 mice of each group were killed, their spleens 
aseptically removed, and splenocytes stimulated with the AMQMLKETI cytotoxic 
peptide, encompassing amino acids p24 (75-83) from HIV-1 Gag. This peptide, 
synthesized using FMOC-chemistry, had above 90% purity as determined by HPLC. 
The number of specific interferon gamma (IFN-γ) producing spleen cells was 
determined by ELISPOT (BD ELISPOT, BD Biosciences) and the levels of IFN-γ 
secreted by splenocytes, by a sandwich ELISA (BD Opteia Set Mouse IFN-γ, BD 
Biosciences), using non-stimulated splenocytes of these mice as controls. In both tests 
1×106 splenocytes were used per well and procedures were carried out following the 
manufacturer’s instructions. Spots were counted using an automated ELISPOT reader. 
Both the number of spots/well and the levels of IFN- obtained from splenocytes were 
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expressed as the mean and SE (n=3) of the individual values obtained after 
AMQMLKETI peptide stimulation minus those obtained in parallel with non-stimulated 
splenocytes. Results were graphically represented as box-plots.  
2.4.2. Humoral response  
Just before challenge (4 weeks after immunization), IgG1 and IgG2a isotype titers were 
determined by an indirect ELISA in sera of immunized mice (n=5). For this, the 
remaining 5 mice of each experimental group were bled (by retrorbital plexus punction, 
under anaesthesia) and serum samples stored at -20ºC until its use. IgGs were 
quantified in 96-well microtiter plates coated by incubation (overnight at 4°C) with 200 
ng/well of p24 protein obtained in the methylotrophic yeast Pichia pastoris (NIBSC, 
WHO-UNAIDS HIV Vaccine Initiative-Health Protection Agency). Serially diluted serum 
samples were added (100 L/well) and, after incubation (1 h at 37ºC), washing and 
blocking, an anti-mouse IgG1 or IgG2a horseradish peroxidase conjugated antibody 
(1:2,000 in blocking buffer) was added and incubated (1 h at 37ºC). After a final 
washing, 2,2′-Azino-bis3-ethylbenzothiazoline-6-sulfonic acid solution (Millipore®) was 
added. Following incubation (30 min at RT), the Optical Density (O.D.) was measured 
at 405 nm in the Multiskan EX apparatus. Serum titer was defined as the reciprocal of 
the highest serum dilution showing a mean O.D. value equal to or greater than that 
shown by the negative control sera plus 3 times the SD. Results were expressed as the 
mean ± SD of individual ratio between log10 IgG2a titer and log10 IgG1 titer.  
2.5. Protection studies in mice 
Groups of 5 BALB/c female mice (8-10 week-old) were inoculated IP with either p24 or 
EDAp24 plus poly(I:C) as detailed above (see point 2.4). A group of mice (n=5) 
inoculated with PBS was used as control. In an additional experiment, the protection 
conferred by EDAp24 plus poly(I:C) was assessed again with respect to PBS control 
and also compared with EDAp24 administered alone. Four weeks after immunization, 
all mice were challenged IP with 1-2×106 CFU/animal of the HIV-1 gag recombinant 
Listeria monocytogenes (Lm-Gag; kindly provided by Dr. Paterson, University of 
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Pennsylvania, USA) and slaughtered 3 days after challenge, in order to determine the 
number of bacteria in spleens as previously described [21]. Briefly, spleens were 
aseptically removed, individually weighed, homogenized (1:10; w/v) and serially diluted 
in PBS. Spleen suspensions were then plated (0.1 mL by triplicate) in LB agar, and 
plates incubated for 24 h at 37ºC (detection limit 4 CFU/spleen). Results were 
expressed as the mean ± SE (n=5) of CFU/spleen, previous logarithmic conversion to 
normalize the intra-group variance. The number of animals free of infection in spleens 
per group was also recorded. 
2.6. Statistical analysis 
The Kolmogorov-Smirnov test was applied to assess the normal distribution of data 
obtained in each experiment. Thereafter, means were statistically compared by a one-
way ANOVA test, followed by the Fisher’s Protected Least Significant Difference 
(PLSD) test. Kruskal-Wallis and Mann-Whitney tests were used for experiments with 
non-normal data distribution. The Statview®Graphics 5.0 for Windows (SAS Institute 
Inc©) statistical package was used in all cases.  
 
3. RESULTS 
3.1. Characterization of EDAp24 and p24 recombinant proteins 
Knowing the immunostimulatory properties of EDA, we produced a fusion protein 
EDAp24 with the aim of inducing anti-p24 T cell responses. Both the fusion protein 
EDA-p24 and p24 were produced, quantified by the Bradford assay and characterized 
by both SDS-PAGE and WB using anti-histidine antibodies. According to the Bradford 
assay, preparations of purified EDAp24 and p24 had a total protein concentration of 
438 and 389 g/mL, respectively. The Coomassie Brilliant Blue staining (Fig. 1A) and 
WB membranes using antibodies against histidine tags (Fig. 1B) yielded results 
compatible with those obtained with p24 and EDA (not shown), revealing the existence 
of bands corresponding to approximately 39, 26 and 13 kDa proteins, the expected 
molecular weight of EDAp24, p24 and EDA, respectively (Figs. 1A and 1B). Moreover, 
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the electrophoretic profiles of p24 in WB showed high molecular weight forms, likely 
corresponding to dimeric and trimeric forms of this recombinant protein (Fig. 1B). This 
was consistent with the protein aggregates observed in p24 but not in EDAp24 
preparations, both macroscopically (as a transparent aggregate) and also by Scanning 
Electron Microscopy (SEM) as polyhedric structures (not shown). Thus, both the 
electrophoretic and SEM results strongly suggest that the conformation of EDAp24 
fusion protein differs from that of the p24 protein. All preparations were free of 
contaminants and endotoxins, as assessed by plating in LB agar and Limulus 
amebocyte lysate assay, respectively. Finally, the antigenicity and conserved antigen 
conformation of both EDAp24 and p24 was confirmed (data not shown) by the 
conformational ELISA sandwich with a mouse anti-p24 monoclonal antibody (described 
in section 2.3).  
3.2. Simultaneous administration of EDA and poly(I:C) enhances the p24 specific 
immune responses 
The induction of specific IFN-γ producing cells and secretion of IFN-γ was assessed in 
the spleens of BALB/c mice immunized with p24 or EDAp24, with or without poly(I:C). 
After stimulation of splenocytes with the cytotoxic AMQMLKETI peptide, IFN-γ 
producing cells were quantified by ELISPOT (Fig. 2A) and IFN-γ secretion levels, by 
ELISA sandwich (Fig. 2B). In both assays, administration of p24 or EDAp24 
recombinant proteins in the absence of poly(I:C) failed to induce a cellular immune 
response, as PBS controls. However, poly(I:C) combined with EDA (administered as 
EDAp24 fusion molecule) induced a significant (p<0.05 vs. PBS, p24 or EDAp24 
groups) p24 specific IFN- cellular immune response, while only a statistical trend 
(p=0.054) was observed when poly(I:C) was administered with p24 alone. A significant 
increase in both IFN-γ producing cells (p0.028; Fig. 2A) and IFN-γ secretion levels 
(p0.012; Fig. 2B), was found in mice immunized with EDAp24 mixed with poly(I:C) 
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compared to those immunized either with p24 plus poly(I:C) or EDAp24 alone, 
indicating a positive coadjuvant effect between EDA and poly(I:C) on IFN-γ production.  
Specific antibody levels (IgG1 and IgG2a isotypes) were measured at the time of 
challenge by an indirect ELISA test, using a commercial p24 protein produced in the 
yeast Pichia pastoris expression system. Results showed that a single immunization 
with EDAp24 or p24, either alone or combined with poly(I:C), was enough to induce 
significant levels of p24-specific IgG1 and IgG2a antibodies in sera of BALB/c mice, in 
comparison with control mice inoculated with PBS (Table 1). Besides, the ratio 
IgG2a/IgG1 indicated slightly higher increased IgG1 levels relative to IgG2a in all the 
p24 immunized mice (Table 1). This ratio was similar in the p24 and EDAp24 groups 
where the antigen was administered jointly with poly(I:C) (0.74  0.16 and 0.71  0.10, 
respectively). The decrease (p≤0.05), in IgG2a levels observed in the group immunized 
with EDAp24 compared to the remaining immunized groups (including p24 group) may 
be due to differences delivering of p24 alone and in the form of EDAp24 fusion protein. 
However, this decrease disappeared when poly(I:C) was included to the immunization 
mixture, suggesting again the possible advantage of using a combination of both 
adjuvants rather than EDA alone (as a fusion protein) to induce antibody production. 
3.3. Simultaneous administration of EDA and poly(I:C) conferred protection 
against Lm-Gag challenge in mice 
To determine the potential of EDA and/or poly(I:C) as an adjuvant system, in the 
context of HIV-1 p24 vaccination, a protection experiment was conducted in BALB/c 
mice (n=5) by administering a single immunization dose with either EDAp24 or p24 
recombinant proteins combined with poly(I:C), followed by challenge with Lm-Gag. 
Protection was expressed as the mean (n=5) log CFU/spleen of the Lm-Gag challenge 
infection in spleens and as the number of mice found with spleens free of infection 
(Table 2). All the mice immunized simultaneously with recombinant p24 and poly(I:C) 
were infected by Lm-Gag, at the levels of unvaccinated controls (Table 2). However, 
the simultaneous immunization with EDAp24 and poly(I:C) prevented mice from 
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virulent infection significantly (p<0.05) compared to both unvaccinated and p24 plus 
poly(I:C) immunized mice. In fact, 3 out the 5 mice immunized with EDAp24 combined 
with poly(I:C) were completely free of infection, whereas most of the unvaccinated mice 
were found infected at levels above 4 logs of Lm-Gag. In an additional experiment, 
results of EDAp24 + poly(I:C) and the PBS control were confirmed and also no 
protection was conferred by EDAp24 in the absence of poly(I:C) (Table 2). Overall, 
these results indicate that the positive immunostimulatory effect of EDAp24 fusion 
protein combined with poly(I:C) encompasses a significant effective protection against 
challenge in mice, and opens a way towards the study and development of a new type 
of HIV vaccines. 
 
4. DISCUSSION 
The main goal of this work was to investigate the potential interest of EDA and poly(I:C) 
as immunostimulators in anti-viral vaccine development, using the HIV-1 protein p24 as 
antigen. This protein is one of the main Gag molecules reported in the study of HIV 
vaccines. HIV Gag-specific T-cell responses appear to dominate in rectal mucosa of 
HIV controllers and, particularly, CD8+ T-cells from HIV-1-infected individuals may 
target a single immunodominant Gag p24 determinant (reviewed by [22]). Thus, the 
enhancement of immune responses to p24 is an important challenge towards the 
development of efficient multicomponent anti-HIV compounds. A number of adjuvants 
have been investigated in order to enhance the immune response to HIV p24 but, to 
our knowledge, few strategies based on protein-adjuvant fusion molecules have been 
explored. Examples of adjuvants used as fusion molecules are those based on cholera 
toxin subunit B [23], hepatitis B core antigen [24], hsp70 from Mycobacterium 
tuberculosis [25] and Ricin subunit B [26]. In previous work, we demonstrated the 
adjuvant effect of EDA when combined with the SIINFEKL ovalbumin peptide [11], NS3 
hepatitis C virus peptide [13] or Human Papilomavirus E7 protein [14]. We have also 
observed that EDA exerts its adjuvant effect more efficiently when delivered not far 
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apart but in close contact with the antigen (San Román et al., submitted for 
publication). Accordingly, the fusion between EDA and p24 would be expected to 
enhance the interaction of p24 with dendritic cells and the antigen-specific immune 
response via TLR4 stimulation. Unlike other adjuvants, EDA has the advantage of its 
innocuousness, avoiding undesirable side effects observed with other adjuvants such 
as Freund’s complete adjuvant or cholera toxin, although to date the use of EDA has 
not been approved. Thus, two recombinant p24 molecules (i.e. p24 and EDAp24 fusion 
protein) were genetically engineered, cloned and individually produced in the E. coli 
BL21-pET20b expression system. EDAp24 was purified from the soluble bacterial 
fraction whereas the p24 protein (produced in the absence of EDA) accumulated in 
inclusion bodies, when expressed in either the auto-inducible or the IPTG induction 
system. This is in contrast with previous studies where p24 was extracted mainly from 
the soluble fraction [27], likely due to the different bacterial expression system 
employed in that study. In any case, conserved protein conformation and maintenance 
of p24 antigen properties were confirmed in both p24 and EDAp24 recombinant 
proteins, as both molecules had the expected molecular weight in WB and p24 
epitopes were recognized with monoclonal antibodies in ELISA sandwich assays. 
Moreover, considering that the combination of two different adjuvants may lead to 
enhancement of the immune response to recombinant proteins [24, 26, 28], we 
hypothesized that the combination of EDA with poly(I:C) would activate different TLRs 
(EDA and poly(I:C) are agonists of TLR-4 and TLR-3, respectively) in the context of 
HIV-1 p24 immunization and would be advantageous through the enhancement of the 
immune response and protection against infection. 
Humoral (IgG isotypes) and cellular (IFN- production) immune responses as well as 
protection against infection, using p24 and EDAp24 recombinant proteins administered 
alone or along with poly(I:C), were assessed in a preclinical mouse model. Since mice 
cannot be infected with HIV-1, a murine model based on challenging with a 
recombinant Listeria monocytogenes expressing HIV-1 Gag proteins (Lm-Gag strain) 
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was used to evaluate the efficacy of anti-HIV vaccines [29, 30]. Protection against 
Listeria involves first the rapid clearance of the majority of bacteria within 12 h of 
infection by resident spleen and liver macrophages. Innate mechanisms including 
neutrophil recruitment, macrophage activation, and secretion of IFN- by NK and δT 
cells are critical in controlling the infection and preventing systemic dissemination 
during the first few days. Thereafter, both CD4 and CD8 T cells contribute to the anti-
listerial cell mediated response [29, 30]. In the mouse model used, IgG antibodies 
produced upon immunization against the p24 may have allowed effective phagocytosis 
against Gag-recombinant Listeria but the antibody levels observed would not explain 
the differences in bacterial clearance between groups. The increased IFN- production 
triggered by the presence of both EDA (as EDAp24 fusion protein) and poly(I:C) may 
be due to increased T cell secretors of this cytokine helping CTLs to clear Gag-
expressing infected cells [30]. Also, Gag-specific T cell activation and lymphokine 
release may have activated macrophages making them competent to kill the 
intracellular bacteria. Furthermore, the complete clearance of p24 recombinant Listeria 
in three of the animals inoculated with both adjuvants strongly suggests the presence 
of a potent CTL response against p24 epitopes. Thus, antibody production in 
conjunction with innate and specific T-cell immunity, may explain the positive effect of 
both adjuvants jointly administered, on protection of p24 immunized mice against p24 
recombinant Listeria.  
The development of an HIV-1 vaccine that elicits cellular and humoral immunity and 
confers a protective effect against HIV-1 infection is still a challenge. The results 
obtained here on IFN-, specific IgG levels and clearance of p24 recombinant Listeria 
(likely via CTL) are encouraging for their application in vaccination against HIV 
infections, knowing that a protective immune response against this virus involves 
ideally the production of neutralizing antibodies, cytotoxic T-cell and T helper immune 
responses [4], activation of NK cells, production of antibody dependent cell cytotoxicity 
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(ADCC) [31] and inhibition of viral replication, referred to as “antibody-dependent cell-
mediated virus inhibition” (ADCVI) (reviewed in [22]). In the mouse model used, IgG 
antibodies to HIV p24 were produced, but these would not be able to neutralize HIV, 
since epitopes for HIV neutralizing antibodies are located in the HIV envelope protein 
[32]. However T-helper cells, activated by increased IFN-, would be expected to help 
not only the development of IgG antibodies addressed to different viral envelope 
proteins, involved in neutralizing and/or ADCC functions [4], but also the production of 
p24-specific CTL responses that, like in the case of recombinant Listeria infected cells, 
would clear the virus infected cells. 
In summary, EDA as a fusion protein with HIV antigens or antigenic epitope 
combinations mixed with poly(I:C) can be proposed as a combined adjuvant candidate 
in the development of new HIV vaccines.  
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Figure captions: 
Fig. 1. SDS polyacrylamide gel electrophoretic patterns of EDAp24 and p24 
recombinant proteins upon Coomassie Brilliant Blue staining (panel A) and anti-
polyhistidine Western-Blot (panel B). Lane 1: Molecular weight marker; lane 2: 
EDAp24; lane 3: p24; lane 4: EDA. Load was equivalent to 2 µg/lane. 
 
 
Fig. 2. EDAp24 administered with poly(I:C) induced significant IFN-γ production in 
BALB/c mice. Animals (n=3) were immunized IP with: i) p24, ii) EDAp24, iii) p24 plus 
poly(I:C), or iv) EDAp24 plus poly(I:C). (A) Number of IFN-γ producing cells measured 
in the ELISPOT assay in the presence or absence of peptide AMQMLKETI and (B) 
levels of IFN-γ determined by the sandwich ELISA, both in cultured spleen cells 
stimulated or not (controls) with AMQMLKETI peptide. ELISPOT and ELISA assays 
were carried out with samples obtained from the same animals. Results are expressed 
as box plot representing the individual values obtained after AMQMLKETI peptide 
stimulation minus those obtained in parallel with non-stimulated splenocytes.  
 
Table 1. Titers of anti-p24 IgG1 and IgG2a isotypes measured by indirect 1 
ELISA in sera of BALB/c mice (n=5) just before challenge, 4 weeks after 2 
intraperitoneal immunization with: i) p24; ii) EDAp24; iii) p24 plus poly(I:C); or iv) 3 
EDAp24 plus poly(I:C). Results of sera from mice inoculated with PBS (controls) 4 
are not presented since all showed undetectable levels of IgG2a and IgG1.  5 
 6 
 7 
a Mean and SD (n=5) of individual log10 IgG titers.  8 
b Mean and SD (n=5) of individual log10 IgG2a/ log10 IgG1 ratio 9 
* p  0.05 vs. other groups. 10 
11 
Immunization log10 IgG1
a log10 IgG2a
a log10 IgG2a/ log10 IgG1
b 
p24 4.11 ± 0.35 3.28 ± 0.75 0.79 ± 0.14 
EDAp24 4.23 ± 0.16 2.48 ± 0.46* 0.59 ± 0.12* 
p24 + poly(I:C) 4.35 ± 0.13 3.20 ± 0.64 0.74 ± 0.16 
EDAp24 + poly(I:C) 4.41 ± 0 3.14 ± 0.45 0.71 ± 0.10 
Table(s)
Table 2. EDAp24 co-administered with poly(I:C) significantly protects mice 12 
against infection by the recombinant Listeria monocytogenes carrying the 13 
gag gene of HIV-1 (Lm-Gag).  14 
 15 
BALB/c mice (n=5) were inoculated intraperitoneally with: i) EDAp24 plus 16 
poly(I:C); ii) EDAp24; iii) p24 plus poly(I:C); or iv) PBS (controls). Four weeks 17 
after inoculation, each mouse was infected intraperitoneally with 1-2×106 18 
CFU of Lm-Gag, and the number of viable bacteria in spleens was 19 
determined 3 days after challenge. Protection is expressed as mean ± SE 20 
(n=5) of log10 CFU/spleen of Lm-Gag. Statistical comparisons of means were 21 
performed by ANOVA and Fisher´s PLSD test (Ap  0.048 vs. other groups), 22 
and the no. of animals infected, by chi-square test (Bp  0.038 vs. other 23 
groups). 24 
 25 
 26 
 27 
Immunization log10 CFU/spleen Lm-Gag 
(mean  SE) 
No. of mice free of  
Lm-Gag infection/totals 
EDAp24 + poly(I:C) 1.74  0.62 A 3/5 
B 
EDAp24 3.74  0.14 0/5 
p24 + poly(I:C) 3.18  0.63 0/5 
PBS 3.53  0.47 0/5 
                          A)                                 B) 
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